RO60 and systemic sclerosis: In SSc patients (n = 43), reactivity against Ro52-1 was more frequent in anti-Ro52+/anti-Ro60+ patients than anti-Ro52+/anti-Ro60– (5/15 [33.3%] vs. 0/28 [0%], p = 0.003) (Table 4).